Cell surface markers are special proteins expressed on the surface of cells or carbohydrates attached to the cell membrane that often conveniently serve as markers of specific cell types. While some proteins have the task of allowing the transport of molecules across the membrane, cell surface markers play a role in inter-cellular communication and recognition. Cell surface markers are used to classify cells according to its markers. This data, in turn, is used to identify different kinds of cells, from cancer cells to stem cells to cells infected with HIV. In short, cell surface markers are like a fingerprint, specific to each kind of cell, and capable of being identified according to what kinds of markers are present on the membrane. Currently, the most common cell surface markers are CD antigen, also known as CD molecules and clusters of differentiation. While CD molecules are very useful in defining leukocytes, they are not merely markers on the cell surface. While only a fraction of known CD molecules have been thoroughly characterized, most of them have an important function. Beyond the mere identification of cells, cell surface markers also hold the potential to aid in drug discovery and especially personalized medicine. With the ability to identify individual cells according to surface markers, scientists are beginning to make breakthroughs in the development of new drugs.
Market Dynamics
Increasing launches of new products, and mergers and acquisitions by key market players is expected to drive the global cell surface markers market growth. For instance, on January 13, 2021, Becton, Dickinson and Company, a U.S. based multinational medical technology company announced the commercial release of the BD AbSeq Immune Discovery Panel (IDP), a state-of-the-art, pre-titrated antibody-oligo based discovery tool designed to investigate 30 immune markers in a single experiment. The BD AbSeq IDP builds upon the advances of the BD AbSeq Assay, which analyzes protein expression at the single-cell level using next-generation sequencing. The BD AbSeq IDP offers researchers convenience, reliability and flexibility as both a multiomics-enabled and cost-efficient tool to aid in immune research and discovery. Also built upon BD antibody-oligo based technology, the BD AbSeq IDP consists of 30 different specificities targeting most major immune markers, conveniently grouped together in a single tube. The panel helps enable immune cell type identification.
Key features of the study:
Detailed Segmentation:
Detailed Segmentation:
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients